SCHEMBL2415633

SCHEMBL2415633

O=[N+]([O-])[C@@H]1CN(Cc2ccccc2)C[C@@H]1c1ccc(Cl)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.40
CCR5 P51681 2/20 0.39
RORC P51449 3/20 0.39
DRD4 P21917 1/20 0.38
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C19 P33261 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPK1 P28482 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
POLB P06746 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
GRIN2B Q13224 1/20 0.36
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1937239 1.00 DPP4 (0.40) DPP4CCR5RORCDRD4DRD2
SCHEMBL2416139 0.90 SIGMAR1 (0.45) DPP4CCR5RORCDRD2DRD3
SCHEMBL1421799 0.90 SIGMAR1 (0.45) DPP4CCR5RORCDRD2DRD3
SCHEMBL1423432 0.90 SIGMAR1 (0.45) DPP4CCR5RORCDRD2DRD3
SCHEMBL1977812 0.86 S1PR1 (0.41) DPP4CCR5RORCCYP1A2CYP2D6
SCHEMBL1977814 0.86 S1PR1 (0.41) DPP4CCR5RORCCYP1A2CYP2D6
SCHEMBL1203016 0.84 RORC (0.45) CCR5RORCDRD2DRD3SIGMAR1
SCHEMBL1975560 0.84 RORC (0.45) CCR5RORCDRD2DRD3SIGMAR1
SCHEMBL1203012 0.84 RORC (0.45) CCR5RORCDRD2DRD3SIGMAR1
SCHEMBL1975169 0.84 CCR5 (0.41) DPP4CCR5RORCCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364295-B1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
US-8293770-B2 Pyrrolidine derivatives as NK-3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-10-23 US disclosed
US-8022099-B2 N-benzyl pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-20 US disclosed
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 US disclosed
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS OPRK1, OPRL1, OPRD1 DPP4 2359/4885CCR5 934/4885RORC 806/4885
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES OPRK1, OPRD1, OPRL1 DPP4 2107/4885CCR5 1534/4885RORC 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.